REGN Regeneron Pharmaceuticals Inc.

569.91
+8.93  (+2%)
Previous Close 560.98
Open 558.12
Price To Book 5.29
Market Cap 64,127,573,165
Shares 112,522,281
Volume 653,533
Short Ratio
Av. Daily Volume 1,274,420
Stock charts supplied by TradingView

NewsSee all news

  1. Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration

    Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration PARIS - May 25, 2020 – Sanofi today announced its intent to sell its equity investment in Regeneron (NASDAQ:REGN)

  2. Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase

    TARRYTOWN, N.Y., May 25, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the commencement of an underwritten public secondary offering of its common stock through which Sanofi

  3. Dupixent® (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints

    TARRYTOWN, N.Y. and PARIS, May 22, 2020 /PRNewswire/ -- Dupixent demonstrated significant clinical and anatomic improvements, including the ability to swallow, in Part A of pivotal trial 69% reduction in disease

  4. Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints

    Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints Dupixent demonstrated significant clinical and anatomic improvements, including the ability to swallow, in Part A of pivotal trial69%

  5. Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio

    TARRYTOWN, N.Y., May 13, 2020 /PRNewswire/ -- Regeneron will host investor webcast on Monday, June 1 to discuss oncology program strategy and progress Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced September 28, 2018.
Cemiplimab
Cutaneous squamous cell carcinoma
FDA Approval announced August 17, 2018.
EYLEA
Wet AMD
sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
PDUFA date May 26, 2020.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
FDA approval announced March 11, 2019.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
FDA approval announced April 26, 2019.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
FDA approval announced October 19, 2018.
Dupixent (dupilumab)
Asthma
Pivotal Phase 2/3 trial ongoing.
REGN2810
Cutaneous squamous cell carcinoma
Phase 3 trial stopped early due to significant improvement in overall survival - April 27, 2020.
Cemiplimab
Non-small cell lung cancer (NSCLC)
Phase 3 enrolling.
REGN2810
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Fasinumab
Osteoarthritis pain of the hip or knee
Phase 3 data released August 14, 2017 - primary endpoint not met.
REGN2222
Respiratory syncytial virus (RSV)
FDA Approval announced May 13, 2019.
EYLEA - PANAROMA
Nonproliferative Diabetic Retinopathy
Phase 3 ongoing.
EYLEA - PROTOCOL-W
Diabetic Retinopathy
Phase 3 data due 4Q 2020.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
FDA Approval announced June 26, 2019.
Dupixent (dupilumab)
Nasal polyps
Phase 2b placed on clinical hold. Phase 3 trial to be initiated that excludes patients with advanced osteoarthritis 2H 2017.
Fasinumab
Osteoarthritis and chronic low back pain
Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.
EYLEA + nesvacumab
Diabetic macular edema (DME)
Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.
EYLEA + nesvacumab
AMD - age-related macular degeneration
Phase 2 data due 2020.
Dupixent (dupilumab)
Peanut Allergy
Data from Phase 2 portion of Phase 2/3 trial met co-primary endpoints - May 22, 2020.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Sarilumab
Rheumatoid arthritis
Phase 1 further data due 2020.
REGN1979
Follicular Lymphoma
BLA has been filed - noted May 5, 2020.
Evinacumab (ANGPTL3 Antibody)
Homozygous familial hypercholesterolemia (HoFH)
Phase 2 data June 21, 2019 met primary endpoint vs placebo. No increased benefit compared to Dupixent.
SAR440340 (REGN3500)
Asthma
Phase 2 data due 3Q 2020.
SAR440340 / REGN3500
Atopic dermatitis
Phase 2 pivotal data showed objective response rate (ORR) of 29%. Regulatory submission due 2020
Cemiplimab
Basal cell carcinoma
Phase 3 enrolment to be completed 2H 2020.
Libtayo - Cemiplimab
Non-small cell lung cancer (NSCLC)
Phase 2 interim data due 2020. Phase 3 trial to be initiated in 2020.
Pozelimab (REGN3918)
Paroxysmal nocturnal hemoglobinuria (PNH
Phase 2 trial did not meet primary endpoint p=0.07 - January 9, 2020. Patient-reported flare-ups were reduced by 50% (nominal p=0.03).
Garetosmab
Fibrodysplasia ossificans progressiva (FOP)
PDUFA date under priority review October 25, 2020.
REGN-EB3
Ebola
Phase 1/2 updated data due 2020.
REGN5458
Multiple Myeloma
Phase 2/3 initial data noted trial to continue with patients with critical disease only ("severe" cohort discontinued due to no benefit). Phase 3 data due June 2020.
Kevzara (Sarilumab)
Coronavirus COVID-19
Human trials to commence June 2020.
REGN-COV2
Coronavirus COVID-19
Phase 2/3 enrolment of global trial has been initiated - march 30, 2020.
Kevzara (sarilumab)
Coronavirus COVID-19
sBLA filing due mid-2020.
Praluent (alirocumab)
Homozygous familial hypercholesterolemia (HoFH)

Latest News

  1. Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration

    Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration PARIS - May 25, 2020 – Sanofi today announced its intent to sell its equity investment in Regeneron (NASDAQ:REGN)

  2. Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase

    TARRYTOWN, N.Y., May 25, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the commencement of an underwritten public secondary offering of its common stock through which Sanofi

  3. Dupixent® (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints

    TARRYTOWN, N.Y. and PARIS, May 22, 2020 /PRNewswire/ -- Dupixent demonstrated significant clinical and anatomic improvements, including the ability to swallow, in Part A of pivotal trial 69% reduction in disease

  4. Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints

    Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints Dupixent demonstrated significant clinical and anatomic improvements, including the ability to swallow, in Part A of pivotal trial69%

  5. Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio

    TARRYTOWN, N.Y., May 13, 2020 /PRNewswire/ -- Regeneron will host investor webcast on Monday, June 1 to discuss oncology program strategy and progress Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the

  6. Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration

    TARRYTOWN, N.Y. and AURORA, Colo., May 11, 2020 /PRNewswire/ -- Regeneron Genetics Center will sequence 450,000 informed and consented patients Sequencing data will be paired with de-identified health records to aid in

  7. Regeneron Reports First Quarter 2020 Financial and Operating Results

    TARRYTOWN, N.Y., May 5, 2020 /PRNewswire/ -- First quarter 2020 revenues increased 33% to $1.83 billion versus first quarter 2019(4) First quarter EYLEA® U.S. net sales increased 9% to $1.17 billion versus first quarter

  8. Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma

    Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma Objective responses seen in 29% of patients with locally advanced basal cell carcinoma (BCC)In a

  9. Libtayo® (cemiplimab) Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma

    TARRYTOWN, N.Y. and PARIS, May 5, 2020 /PRNewswire/ --   Objective responses seen in approximately 29% of patients with locally advanced basal cell carcinoma (BCC) In a preliminary analysis, objective responses seen in

  10. Regeneron Announces Upcoming Investor Conference Presentations

    TARRYTOWN, N.Y., April 29, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Bank of America Securities Virtual Health Care Conference at 8:20 a.m. ET

  11. Sanofi: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival

    Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival               Libtayo decreased the risk

  12. Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival

    TARRYTOWN, N.Y. and PARIS, April 27, 2020 /PRNewswire/ -- Libtayo decreased the risk of death by 32.4% compared to chemotherapy Regeneron and Sanofi plan regulatory submissions in 2020 Regeneron Pharmaceuticals,

  13. Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients

    Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more

  14. Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients

    TARRYTOWN, N.Y. and PARIS, April 27, 2020 /PRNewswire/ --  Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced "critical" group with Kevzara higher-dose

  15. FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola

    TARRYTOWN, N.Y., April 16, 2020 /PRNewswire/ --  REGN-EB3 developed via same rapid response platform currently being leveraged to develop novel COVID-19 antibody therapyRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today

  16. Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)

  17. Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)

  18. STAT News Reporter Says CEOs Of Amgen, Genentech, Gilead And Regeneron Were Involved In Call With Trump

  19. Sanofi Finalizes Praluent Restructuring With Regeneron

  20. Regeneron Finalizes Praluent® (alirocumab) Restructuring and Updates Accounting Presentation

  21. Sanofi: Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years

    Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years Detailed data to be presented at the Revolutionizing Atopic Dermatitis Conference show

  22. Dupixent® (dupilumab) Phase 3 Data at Revolutionizing Atopic Dermatitis Conference Show Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years

    TARRYTOWN, N.Y. and PARIS, April 3, 2020 /PRNewswire/ -- Patients who added Dupixent to topical corticosteroids improved skin clearance; average overall disease improved by approximately 80% based on mean EASI

  23. Sanofi: First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19

    Phase 2/3 trial initiated in Italy, Spain, Germany, France, Canada and Russia and is enrolling patients immediatelyKevzara inhibits IL-6, which may play a role in driving the inflammatory immune response that causes

  24. Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol

    TARRYTOWN, N.Y., March 30, 2020 /PRNewswire/ --  Results from separate positive Phase 3 trial of Praluent® (alirocumab) in patients with HoFH also presented; FDA regulatory submission planned for Q2 2020 Regeneron

  25. Sanofi: First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19

    First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19 Phase 2/3 trial initiated in Italy, Spain, Germany, France, Canada and Russia and is

  26. First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19

    TARRYTOWN, N.Y. and PARIS, March 30, 2020 /PRNewswire/ --  Phase 2/3 trial initiated in Italy, Spain, Germany, France, Japan, Canada and Russia and is enrolling patients immediately Kevzara inhibits IL-6, which may play

  27. Regeneron Announces Important Advances in Novel COVID-19 Antibody Program

    TARRYTOWN, N.Y., March 17, 2020 /PRNewswire/ -- Regeneron has identified hundreds of virus-neutralizing antibodies; plans to initiate large-scale manufacturing by mid-April with antibody cocktail therapy Potential to

  28. Regeneron and Sanofi Begin Global Kevzara® (sarilumab) Clinical Trial Program in Patients with Severe COVID-19

    TARRYTOWN, N.Y. and CAMBRIDGE, Mass., March 16, 2020 /PRNewswire/ -- U.S. Phase 2/3 trial initiated and will begin enrolling patients immediately Regeneron is leading U.S. trials, Sanofi will lead upcoming ex-U.S.

  29. Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19

    CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc today announced they have started a clinical program evaluating Kevzara® (sarilumab) in patients hospitalized

  30. Regeneron Announces Upcoming Investor Conference Presentations

    TARRYTOWN, N.Y., March 3, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: J.P. Morgan 2020 Biotech Conference Call Series at 12:00 p.m. ET on Friday,

  31. Regeneron Announces Upcoming Investor Conference Presentations

    TARRYTOWN, N.Y., Feb. 12, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows: SVB Leerink 9th Annual Global Healthcare Conference at 10:00 a.m. ET on

  32. EYLEA® (aflibercept) Injection Reduced Risk of Developing Vision-Threatening Events by 75% After Two Years in Patients with Diabetic Retinopathy

    TARRYTOWN, N.Y., Feb. 8, 2020 /PRNewswire/ -- New data highlight importance of proactive EYLEA treatment as more than half of untreated patients in PANORAMA developed vision-threatening events over two years High-dose

  33. Regeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results

    TARRYTOWN, N.Y., Feb. 6, 2020 /PRNewswire/ -- Fourth quarter 2019 revenues increased 13% to $2.17 billion versus fourth quarter 2018 Fourth quarter EYLEA® U.S. net sales increased 13% to $1.22 billion versus fourth

  34. Regeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New Coronavirus

    TARRYTOWN, N.Y., Feb. 4, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced an expanded agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments

  35. Sanofi : FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis

    FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis *If approved, Dupixent would be the first biologic medicine available in the U.S. for these

  36. FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis

    TARRYTOWN, N.Y. and PARIS, Jan. 28, 2020 /PRNewswire/ -- If approved, Dupixent would be the first biologic medicine available in the U.S. for these children Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi

  37. Forty of the Nation's Brightest Young Scientists Named Finalists in Regeneron Science Talent Search 2020

    TARRYTOWN, N.Y. and WASHINGTON, Jan. 22, 2020 /PRNewswire/ -- Finalists to Compete for More Than $1.8 Million in Oldest and Most Prestigious U.S. STEM Competition for High School Seniors Females represent more than 50

  38. Regeneron to Report Fourth Quarter and Full Year 2019 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2020

    TARRYTOWN, N.Y., Jan. 10, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2019 financial and operating results on Thursday,

  39. Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease

    TARRYTOWN, N.Y., Jan. 9, 2020 /PRNewswire/ --  Approximately 25% decrease in total bone lesions (both new and existing) driven by nearly 90% reduction in formation of new lesions in patients with fibrodysplasia

  40. Publication Highlights Regeneron's Costimulatory Bispecific Antibodies, an Emerging Class of Cancer Immunotherapy

    TARRYTOWN, N.Y., Jan. 8, 2020 /PRNewswire/ -- Preclinical results published in Science Translational Medicine show that adding CD28 costimulatory bispecifics to CD3 bispecifics led to synergistic anti-tumor activity

  41. Regeneron Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

    TARRYTOWN, N.Y., Dec. 20, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020.  The

  42. Society for Science & the Public Announces Regeneron as New Title Sponsor of the International Science and Engineering Fair

    TARRYTOWN, N.Y. and WASHINGTON, Dec. 12, 2019 /PRNewswire/ -- Regeneron ISEF gathers outstanding science students from around the globe to compete for millions in prizes at the world's largest pre-college science

  43. Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)

    Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab) PARIS (FRANCE) AND TARRYTOWN, NY - December 10, 2019 – Sanofi and Regeneron

  44. Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)

    TARRYTOWN, N.Y. and PARIS, Dec. 10, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced their intent to simplify their antibody collaboration for Kevzara® (sarilumab) and

  45. First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma

    TARRYTOWN, N.Y., Dec. 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory

  46. Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder

    TARRYTOWN, N.Y., Dec. 5, 2019 /PRNewswire/ -- Results from initial 6-patient cohort show pozelimab reduced lactate dehydrogenase (LDH) to normal levels at week 8 in patients with paroxysmal nocturnal hemoglobinuria

  47. New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths

    TARRYTOWN, N.Y., Nov. 27, 2019 /PRNewswire/ -- Nearly 90 percent survival for patients who received REGN-EB3 treatment earlier in the course of their disease; 66.5 percent survival among all patients who received

  48. Regeneron's Yancopoulos Receives Columbia College's Alexander Hamilton Award

    TARRYTOWN, N.Y., Nov. 22, 2019 /PRNewswire/ -- Columbia's highest honor bestowed for Yancopoulos' contributions to science and medicine Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that George D.

  49. Regeneron Announces Upcoming Investor Conference Presentations

    TARRYTOWN, N.Y., Nov. 12, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will webcast management presentations as follows: Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day, at 11:15 a.m.

  50. Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer

    TARRYTOWN, N.Y. and ROCHESTER, Minn., Nov. 6, 2019 /PRNewswire/ -- Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration

  51. Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)

    80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months PLYMOUTH MEETING, Pa., Nov. 5, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today

  52. Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer

    TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today provided an update on the ongoing Phase 3 development program evaluating Libtayo® (cemiplimab), a PD-1 inhibitor, as

  53. Regeneron Reports Third Quarter 2019 Financial and Operating Results

    TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ -- Third quarter 2019 revenues increased 23% to $2.05 billion versus third quarter 2018 Third quarter EYLEA® U.S. net sales increased 16% to $1.19 billion versus third quarter

  54. Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis

    Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis First biologic approved in the European Union for adults with severe chronic rhinosinusitis with nasal

  55. Regeneron Ranked #2 in Science Magazine's Top Biopharma Companies to Work For

    TARRYTOWN, N.Y., Oct. 25, 2019 /PRNewswire/ --  Regeneron is the most highly ranked company over the past decade Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the company was once again ranked as a

  56. Regeneron Colleagues Support 150 Community Organizations During Third Annual Day for Doing Good

    TARRYTOWN, N.Y., Oct. 25, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today celebrates its third annual Day for Doing Good, a company-wide global day of service. Reflecting Regeneron's

  57. Regeneron Announces Upcoming Investor Conference Presentations

    TARRYTOWN, N.Y., Oct. 18, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows: Credit Suisse 28th Annual Healthcare Conference at 10:00 a.m. EST

  58. Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019

    TARRYTOWN, N.Y., Oct. 10, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2019 financial and operating results on Tuesday, November 5, 2019,

  59. The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Sept. 20, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that The Lancet has published detailed positive results from two Phase 3

  60. Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis

    CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis   PARIS and TARRYTOWN, NY – September 20, 2019 – The European Medicines Agency's Committee for Medicinal

  61. CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis

    TARRYTOWN, N.Y. and PARIS, Sept. 20, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use

  62. Educational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Dermatitis

    TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Sept. 18, 2019 /PRNewswire/ --  Understand AD program brings together a team of experts to help a teen with severe atopic dermatitis (AD) and his parents navigate the

  63. Regeneron Debuts on Prestigious Dow Jones Sustainability World Index of Most Sustainable Companies

    TARRYTOWN, N.Y., Sept. 17, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the company was added to the Dow Jones Sustainability World Index (DJSI World) for the first time.

  64. Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9

    U.S. District Court invalidates Amgen patent claims targeting PCSK9 Court rules in favor of Sanofi and Regeneron in ongoing Praluent® (alirocumab) patent litigation PARIS and TARRYTOWN, NY – August 28, 2019 –

  65. U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9

    TARRYTOWN, N.Y. and PARIS, Aug. 28, 2019 /PRNewswire/ -- Court rules in favor of Regeneron and Sanofi in ongoing Praluent® (alirocumab) patent litigation  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi